Lege Artis Medicinae

[RECENT ADVANCEMENTS IN THE DIAGNOSIS AND TREATMENT OF AGE-RELATED MACULAR DEGENERATION]

SERES András István

APRIL 22, 2008

Lege Artis Medicinae - 2008;18(04)

[Age-related macular degeneration is the leading cause of blindness in developed countries. In the last few years, new therapeutic approaches such as photodynamic therapy and intravitreal injections of vascular endothelial growth factor antagonists were introduced that do not only prevent disease progression but also give the hope of vision improvement. Of the new diagnostic methods, the use of optical coherence tomography improves diagnosis and also permits the qualitative measurement of therapeutic effects. Given the current high price of the new drugs and the need for frequent re-treatments, a significant increase in the economic burden of the disease is foreseeable.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[27th congress of the Society of Hungarian Oncologists]

LANDHERR László

Lege Artis Medicinae

[Homosexuality from a Medical Perspective]

KÓRÁSZ Krisztián, KORAS Réka, SIMON Lajos

Lege Artis Medicinae

[Polydactylic Human Figures on North American Stone Paintings]

dr. NAGY Gyula

Lege Artis Medicinae

[The features of the MEDAL Programme and critical evaluation of the results]

NEMESÁNSZKY Elemér

Lege Artis Medicinae

[Facts and myths in the management of acute stroke]

CSIBA László, KOVÁCS Katalin Réka

All articles in the issue

Related contents

Clinical Neuroscience

[ASSOCIATION OF APOLIPOPROTEIN E POLYMORPHISM WITH AGE-RELATED MACULAR DEGENERATION AND ALZHEIMER’S DISEASE IN SOUTH-WESTERN HUNGARY]

KOVÁCS Katalin Á., PÁMER Zsuzsanna, KOVÁCS Attila, FEKETE Sándor, MISETA Attila, KOVÁCS Bálint, KOVÁCS Gábor L.

[Background - Age-related macular degeneration (AMD) and Alzheimer dementia (AD) show similarities (advanced age, formation of deposits of similar content). Recently apolipoprotein E 2 (apoE 2) has been associated with AMD, while apoE4 with AD. The question of coexistence, especially with respect to the genetic background has not been studied earlier. We investigated, therefore, the occurrence of AMD in AD patients and compared their lipid profile and apoE polymorphism. Methods - 49 AMD, 32 AD and 27 control patients were examined (risk factors, visual acuity, slit lamp biomicroscopy, fundoscopy). Following measurement of triglyceride, total and HDL cholesterol levels, apoE mutation analysis was performed. Results - AMD was found in 8% of the cooperating AD patients. The prevalence of the apoE 4 isoforms in the AMD, AD and the control patients was 2%, 47% and 22%, while that of apoE 2 was 17%, 6% and 7%, respectively. The prevalence of apoE 3 isoform was 82%, 41% and 71%, respectively. Triglyceride, total and HDL cholesterol were in the reference range; however, AD patients were characterized by a lower total cholesterol value. Conclusions - The new finding of this publication is the rare occurrence of AMD among AD patients. The higher frequency of apoE 4 among the AD population, and the higher frequency of apoE 2 among AMD patients in the South-Western region of Hungary confirms the findings of other investigators.]

Clinical Oncology

[Challenges in Molecular Targeted Therapy for Gastric Cancer: Considerations for Effi cacy and Safety]

KEI Muro

[The Cancer Genome Atlas Research Network recently proposed a molecular classifi cation for gastric cancer (GC) into four subtypes based on comprehensive evaluation. While the mechanisms of molecular targeted therapies in GC were confi rmed by multiple clinical studies, only a limited number of therapeutics for GC have been approved to date. In this systematic review of the available literature, we discuss the completed and ongoing clinical trials of molecular targeted therapies in patients with GC, with a focus on their effi cacy and safety. Results of recent studies clearly demonstrated that trastuzumab and ramucirumab, monoclonal antibodies (mAbs) against human epidermal growth factor receptor 2 (HER2) and vascular endothelial growth factor (VEGF), respectively, improved overall survival (OS) in GC with manageable safety profi les. Careful surveillance of ongoing clinical trials and timely profi ling and monitoring of genetic signatures are imperative to establish a strong foundation for precision medicine in GC.]

Lege Artis Medicinae

[News in the therapy of age-related macular degeneration]

RÉCSÁN Zsuzsa

[Age-related macular degeneration is the leading cause of serious visual deterioration in elderly people. The progressive, degenerative maculopathy involves both eyes. The serious visual impairment is caused by geographic atrophy and subretinal neovascularization. Interaction between environmental and genetic factors is fundamental in the development of this multifactorial disease. Significant risk factors are the age, positive familiy history and smoking. In early stages, prevention and vitamin supplementation play important role. Modern therapy of subretinal neovascularization is the inhibition of VEGF. No known treatment has been yet available for geographic atrophy.]